Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study - Takeaways - MDSpire

Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study

  • By

  • Ma Wanda

  • Lei Mengjie

  • Wang Jingyao

  • Sun Xue

  • Wang Xiao

  • Li Cairong

  • Li Yachao

  • Zhao Zhigang

  • Xue Zengming

  • May 1, 2026

  • 0 min

Share

  • 1

    The study evaluated single antiplatelet therapy outcomes in high-risk acute coronary syndrome patients after transitioning from dual antiplatelet therapy.

  • 2

    Clopidogrel therapy resulted in significantly lower rates of major adverse cardiovascular and cerebrovascular events compared to aspirin.

  • 3

    The occurrence of net adverse clinical events was similar between aspirin and clopidogrel cohorts, indicating no increased bleeding risk with clopidogrel.

  • 4

    Cox regression analysis showed that clopidogrel reduced the hazard of major adverse cardiovascular events and target vessel revascularization.

  • 5

    The findings suggest clopidogrel may be a preferable option for long-term antiplatelet therapy in high-risk ACS patients post-PCI.

Original Source(s)

Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study

  • by Ma Wanda, Lei Mengjie, Wang Jingyao, Sun Xue, Wang Xiao, Li Cairong, Li Yachao, Zhao Zhigang, Xue Zengming

  • May 1, 2026

Related Content

Medical Oddities: Muscle Memory Before Birth? 

When dad trains offspring gain, bar tricks can end in the OR, guts that linger, empathetic pain, and “natural” immune traps this week.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Flu Vaccination Linked to Lower Heart, Stroke Risk After Infection

A Danish registry study suggests prior influenza vaccination is associated with lower short-term cardiovascular risk following breakthrough infection.